Inhibikase Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.04.24	Inhibikase Announces Pre-IND Meeting For IkT-001Pro - Quick Facts (RTTNews)
04.12.23	Inhibikase Therapeutics Gets FDA's Pre-NDA Meeting For IkT-001Pro (RTTNews)
04.10.23	Inhibikase Therapeutics Announces Orphan Drug Designation For Risvodetinib (RTTNews)
24.08.23	Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib (PR Newswire)
22.08.23	Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders (PR Newswire)
21.08.23	Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib (PR Newswire)
17.08.23	Inhibikase: 600 Mg IkT-001Pro Shows Bioequivalence To 400 Mg Dose Of Imatinib Mesylate (RTTNews)
17.08.23	Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro (PR Newswire)
14.08.23	Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity (PR Newswire)
07.08.23	Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023 (PR Newswire)
28.07.23	Pre-market Movers: SIGA, SNBR, BLUA, SNTG, PRZO… (RTTNews)
17.07.23	Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements (PR Newswire)
29.06.23	Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split (PR Newswire)
22.06.23	Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study (PR Newswire)
21.06.23	Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease (PR Newswire)
30.05.23	Inhibikase Therapeutics to Present at the LD Micro Invitational XIII (PR Newswire)
16.05.23	Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease (PR Newswire)
15.05.23	Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity (PR Newswire)
08.05.23	Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023 (PR Newswire)
04.05.23	Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference (PR Newswire)
26.04.23	Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease (PR Newswire)
21.04.23	Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase (PR Newswire)
31.03.23	Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity (PR Newswire)
23.03.23	Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023 (PR Newswire)
21.03.23	Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (PR Newswire)
16.03.23	Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023 (PR Newswire)
15.03.23	Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro (PR Newswire)
08.03.23	Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy (PR Newswire)
15.02.23	Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit (PR Newswire)
27.01.23	Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules (PR Newswire)
25.01.23	Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules (PR Newswire)
25.01.23	Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders (PR Newswire)
25.01.23	Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease (PR Newswire)
12.12.22	Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro (PR Newswire)
07.12.22	Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs (PR Newswire)
22.11.22	Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
14.11.22	Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity (PR Newswire)
08.11.22	Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022 (PR Newswire)
07.11.22	Inhibikase: FDA Issues Clinical Hold On IkT-148009 Programs - Quick Facts (RTTNews)
07.11.22	Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs (PR Newswire)
12.10.22	Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference (PR Newswire)
21.09.22	Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference (PR Newswire)
15.09.22	Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress (PR Newswire)
08.09.22	Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders (PR Newswire)
01.09.22	Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors (PR Newswire)
26.08.22	Inhibikase Says FDA Clears IND For IkT-001Pro To Treat Chronic Myelogenous Leukemia (RTTNews)
26.08.22	Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia (PR Newswire)
23.08.22	Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease (PR Newswire)
12.08.22	Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity (PR Newswire)
08.08.22	Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Inhibikase Therapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten